^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SF2535

i
Other names: SF2535, SF 2535
Associations
Trials
Company:
SignalRx
Drug class:
PI3K inhibitor, BET inhibitor, BRD4 inhibitor
Related drugs:
Associations
Trials
over2years
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. (PubMed, Front Oncol)
Previously, combination of BRD4 and PI3K inhibition with SF2523 was shown to successfully decrease Myc expression. Interestingly, SF2535 decreased the mean fluorescence intensity (MFI) of integrin α4, α5, α6, and β1 while increasing MFI of CXCR4, indicating that SF2535 may work through inside-out signaling of integrins. Taken together, our data provide a rationale for the clinical evaluation of targeting PI3Kδ/BRD4 in refractory or relapsed B-ALL using SF2535.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • BRD4 (Bromodomain Containing 4) • ITGA4 (Integrin, alpha 4) • CASP7 (Caspase 7)
|
MYC overexpression • MYC expression
|
SF2523 • SF2535